SecBot SecBot

AQST

Aquestive Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001398733 Biotech & Drug Discovery
$3.97 −0.03 (−0.75%)
Oct 26 4:00 PM ET · prev $4.00
Market cap
$518.4M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$10.00
+152% · range $6.00–11.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.14
1 year
−43.3%
from $7.00 · Oct 27
30 days
−16.4%
from $4.75
52-week range
$2.95–7.00
−43% from high · low Jan 30
Avg volume 20D
2.17M
Oct 15 spike 5.47M
Short interest
28.75M
≈22.9% of shares · +5.8%
Days to cover
13.1
at average volume
Insider net
−$2.4M
0 buyers · 8 sellers · since Mar 9
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read BULLISH 12 reports · 90 days
Balance 1 bearish · 5 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 9/12 ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    8 insiders sold $2.4M.

  • InstitutionsMIXED

    Q2 2026: 13 added (1 new), 11 trimmed or exited. Largest new: Vanguard Capital Management $19.1M.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.110 → −$0.135 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.8% to 28.75M shares. 13.1 days to cover, ≈22.9% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 13.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$19.1M
in new stakes
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCNEW4,584,533$19.1M
BANK OF AMERICA CORP /DE/TRIM1,668,423$6.9M
WASATCH ADVISORS LPADD1,385,843$5.8M
Nuveen, LLCDOUBLED1,215,225$5.1M
BALYASNY ASSET MANAGEMENT L.P.TRIM744,536$3.1M
MORGAN STANLEYTRIM658,617$2.7M
JANE STREET GROUP, LLCTRIM437,490$1.8M
MARSHALL WACE, LLPDOUBLED285,659$1.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy10Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +152%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Reddit
Recent posts
r/Shortsqueeze Bullish 13d ago
AQST 13 days to cover short. GoGetEm
0 upvotes · 2 comments
r/Shortsqueeze Bullish 13d ago
Primed to buy AQST. Short squeeze STRONG
1 upvotes · 2 comments
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$2.4M
sold · 8 insiders
DateInsiderTypeValue
Oct 21, 2026
Cochran John
Director
OTHER62,229 sh
Oct 15, 2026
Barber Daniel
President and CEO
SELL$105.6K
Sep 15, 2026
Barber Daniel
President and CEO
SELL$120.5K
Sep 9, 2026
Korczynski Sherry
Chief Commercial Officer
EXERCISE$23.2K
Sep 9, 2026
Korczynski Sherry
Chief Commercial Officer
SELL$45.7K
Sep 9, 2026
Boyd Peter E.
Chief People Officer
EXERCISE$2.2K
Sep 9, 2026
Boyd Peter E.
Chief People Officer
EXERCISE2,293 sh
Sep 8, 2026
Barber Daniel
President and CEO
EXERCISE$88.1K

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.14
EPS estimate, this quarter
−23%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.14-$0.15–-$0.12-12.5%$11.0M
Next Q-$0.14-$0.15–-$0.13-12.0%$11.7M
Current FY🔒 Fresh data, subscribers only
Next FY-$0.57-$0.70–-$0.44-26.7%$67.8M

Short side

FINRA· Sep 30, 2026
28,748,212
shares short
+5.8%
vs prior settlement
13.1
days to cover
≈22.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Insider
Cochran John acquired 62,229 shares
Director
Oct 15, 2026 SEC
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for…
8-K — Impact 7/10
Oct 15, 2026 Press
Aquestive Therapeutics announced FDA acceptance of its resubmitted NDA for Anaphylm (dibutepinephrine) sublingual film…
Impact 7/10
Oct 15, 2026 FDA
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug U
Oct 15, 2026 Insider
Barber Daniel sold 25,000 shares
President and CEO @ $4.22 ($105.6K)
Oct 14, 2026 SEC
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal…
8-K — Impact 6/10
Oct 7, 2026 SEC
Edward P. Bass and his affiliated entity Thru Line L.P. filed a new Schedule 13G disclosing beneficial ownership of…
SC 13G — Impact 3/10
Sep 15, 2026 Insider
Barber Daniel sold 25,000 shares
President and CEO @ $4.82 ($120.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
AQST Q3 2026 Earnings After Market Close — 2026-11-09
Mar 16, 2027
FDA decision date
PDUFA: AQST — Anaphylm in Type I allergic reactions, including anaphylaxis — 2027-03-16
FDA target action date 2027-03-16 for AQST (Aquestive Therapeutics, Inc.). Drug: Anaphylm. Indication: Type I allergic reactions, including…
Mar 29, 2027
FDA decision date
PDUFA: AQST — LIBERVANT in seizure clusters, acute repetitive seizures in epilepsy — 2027-03-29
FDA target action date 2027-03-29 for AQST (Aquestive Therapeutics, Inc.). Drug: LIBERVANT. Indication: seizure clusters, acute repetitive seizures…
Recent
Oct 15, 2026
FDA
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for…
Sep 17, 2026
Press release
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical…
Aug 31, 2026
Short interest
Short Interest: AQST up 22% to 25.5M shares
Settlement 2026-08-31 | Days to cover: 7.15 | ≈20.30% of shares outstanding (est.)
Aug 11, 2026
Earnings
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company…
Aug 11, 2026
Earnings date
AQST Q2 2026 Earnings After Market Close — 2026-08-11

SecBot reports

16 filings · 2 press releases · 5 bullish · 2 bearish · 2 mixed · 7 neutral
All AQST filing & press-release reports (18)